search
Back to results

Antioxidant Use in Diabetes to Reduce Oxidative Stress

Primary Purpose

Ameliorating Oxidative Stress in Type 1 Diabetes

Status
Terminated
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
N-acetyl cysteine
omega 6 Fish oil ( PUFA)
Placebo
Sponsored by
University of Maryland, Baltimore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ameliorating Oxidative Stress in Type 1 Diabetes

Eligibility Criteria

18 Years - 44 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • hemoglobin a1c <10
  • type 1 diabetes

Exclusion Criteria:

  • pregnancy
  • BMI > 40
  • greater than 1 alcoholic beverages per week
  • any tobacco use
  • prescribed nitroglycerin, HIV protease inhibits, corticosteroids, cephalosporins, or blood thinners
  • vascular complications(history of coronary artery disease, cerebral vascular accident, transient ischemic attack, claudication).

Sites / Locations

  • University of Maryland, Baltimore

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

N-acetylcysteine 600 mg

N-acetylcysteine 1200 mg

placebo

PUFA 1000 mg

PUFA 2000 mg

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Change from baseline in level of oxidative stress with varying doses of NAC at 2 weeks.
Change from baseline in level of oxidative stress with varying doses of omega 6 fish oil(PUFA) at 2 weeks.

Secondary Outcome Measures

Full Information

First Posted
January 30, 2017
Last Updated
March 7, 2022
Sponsor
University of Maryland, Baltimore
search

1. Study Identification

Unique Protocol Identification Number
NCT03056014
Brief Title
Antioxidant Use in Diabetes to Reduce Oxidative Stress
Official Title
Supplementation of N-acetylcysteine and Arachonic Acid in Type 1 Diabetes to Determine Changes in Oxidative Stress
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Terminated
Why Stopped
COVID
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
March 12, 2020 (Actual)
Study Completion Date
March 12, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Maryland, Baltimore

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Dietary supplementation with antioxidant vitamins, such as Vitamin C and Vitamin E, reduces malformation rates in embryos of diabetic animals. However, human trials exploring the benefits of these antioxidant vitamins have produced unsatisfactory results in trials designed to alleviating diabetic retinopathy, cardiovascular disease, and preeclampsia in pregnancies. The investigators hypothesize that more potent, and better-targeted antioxidants, such as N-acetylcysteine (NAC) and Polyunsaturated Fatty Acids(PUFA), will be successful in preventing birth defects in the offspring of women with diabetes.
Detailed Description
Specific Aim 1. Recruit non pregnant women with T1DM and investigate the efficacy of dietary NAC on ameliorating oxidative stress Study design. Diabetic patients will be provided with NAC or placebo for 14 days, while receiving usual clinical care. The oxidative stress status will be assessed by measuring biomarkers in blood samples pre and post intervention. In addition to a placebo control group, three treatment groups including Group 1 (NAC 600 mg/day), Group 2 (NAC 1200 mg/day), and Group 3 (NAC 1800 mg/day) will be studied. The choice of dosage of NAC is based on published studies, which show effectiveness of NAC in 600 or 1200 mg day in alleviating oxidative stress in diabetic patients, both in men and women, without adverse side effects. The investigators will use the supplement company TwinLab for our study. The university of Maryland Pharmacy department will analyze the NAC for purity prior to starting the study. At day 7, participants will be called via phone assess for symptoms and side effects from medications. All participants will be called. At the end of 14 days, the patients will return to the CDE with a survey asking about compliance with medication and any side effects. They will also bring the pill bottle so that study personnel can do a pill count. At this time blood will be draw for the biomarker levels to look for changes in oxidative stress. Specific Aim 2. To investigate effect of PUFAs on ameliorating oxidative stress in diabetic non-pregnant women. Study design: The investigators will recruit a new group of Non-pregnant women with T1DM will be enrolled and randomly assigned to placebo or one of three treatment groups. Study volunteers will be divided into 1 of 3 groups. PUFA; Group 1 (1000 mg/day) or Group 2 (2000 mg/day) or Group 3(placebo). The treatment regimens, sample collection, biomarker assessment, side effect monitoring and statistical analysis will be performed as described in SA 1. The investigators will perform an analysis of the oxidative stress biomarkers as described in SA1. The investigators will use TwinLab as our commercial supplier of PUFA for our trial. There fish oil supplements have been involved in greater than 40 published trials. The fish oil supplement will be analyzed by the University of Maryland pharmacy department prior to starting the study to analyze for purity. Specific Aim 3: To investigate the potential secondary benefit of NAC/PUFA on kidney function and lipid profile. Urine and serum samples will be collected on all enrolled subjects at day 0 and Day 14 to monitor for improvement in microalbumin in the urine and lipid profile in the serum. Previous studies have shown improvements in LDL with supplementation of NAC. The investigators will look at how various dosages effect the improvement in microalbumin and lipid profile.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ameliorating Oxidative Stress in Type 1 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
Double blind
Allocation
Randomized
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
N-acetylcysteine 600 mg
Arm Type
Active Comparator
Arm Title
N-acetylcysteine 1200 mg
Arm Type
Active Comparator
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Title
PUFA 1000 mg
Arm Type
Active Comparator
Arm Title
PUFA 2000 mg
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
N-acetyl cysteine
Intervention Description
giving varying doses of NAC in order to determine which reduces oxidative stress.
Intervention Type
Dietary Supplement
Intervention Name(s)
omega 6 Fish oil ( PUFA)
Intervention Description
giving varying doses of PUFA in order to determine which reduces oxidative stress.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
L-alanine placebo pill to determine if effect is supplement related or random effect.
Primary Outcome Measure Information:
Title
Change from baseline in level of oxidative stress with varying doses of NAC at 2 weeks.
Time Frame
2 weeks
Title
Change from baseline in level of oxidative stress with varying doses of omega 6 fish oil(PUFA) at 2 weeks.
Time Frame
2 weeks

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
we specifically want to study this in reproductive age females.
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
44 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: hemoglobin a1c <10 type 1 diabetes Exclusion Criteria: pregnancy BMI > 40 greater than 1 alcoholic beverages per week any tobacco use prescribed nitroglycerin, HIV protease inhibits, corticosteroids, cephalosporins, or blood thinners vascular complications(history of coronary artery disease, cerebral vascular accident, transient ischemic attack, claudication).
Facility Information:
Facility Name
University of Maryland, Baltimore
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Antioxidant Use in Diabetes to Reduce Oxidative Stress

We'll reach out to this number within 24 hrs